Techno Drugs And Intermediates Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 9.00 M
as on 21-12-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.26 Cr
as on 21-12-2024
- Satisfied Charges ₹ 2.88 Cr
as on 21-12-2024
- Revenue 11.64%
(FY 2023)
- Profit -55.65%
(FY 2023)
- Ebitda -52.66%
(FY 2023)
- Net Worth 10.35%
(FY 2023)
- Total Assets -11.98%
(FY 2023)
About Techno Drugs And Intermediates
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 9.00 M.
The company currently has active open charges totaling ₹10.26 Cr. The company has closed loans amounting to ₹2.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sameer Gandhi and Kiranavali Gandhi serve as directors at the Company.
- CIN/LLPIN
U24139MH1992PTC065739
- Company No.
065739
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Techno Drugs And Intermediates Private Limited offer?
Techno Drugs And Intermediates Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Anti Infective API.
Who are the key members and board of directors at Techno Drugs And Intermediates?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sameer Gandhi  | Director | 15-Mar-1992 | Current |
| Kiranavali Gandhi | Additional Director | 26-Jul-2021 | Current |
Financial Performance of Techno Drugs And Intermediates.
Techno Drugs And Intermediates Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.64% increase. The company also saw a substantial fall in profitability, with a 55.65% decrease in profit. The company's net worth Soared by an impressive increase of 10.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Techno Drugs And Intermediates?
Unlock access to Techno Drugs And Intermediates's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Oct 2013 | ₹8.76 Cr | Open |
Central Bank Of India Creation Date: 19 Oct 2013 | ₹1.50 Cr | Open |
Idbi Bank Limited Creation Date: 05 Jul 2011 | ₹2.20 Cr | Satisfied |
How Many Employees Work at Techno Drugs And Intermediates?
Unlock and access historical data on people associated with Techno Drugs And Intermediates, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Techno Drugs And Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Techno Drugs And Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
